Indium (In111) Chloride Curium Netherlands

Indium-111 chloride, the active ingredient in Indium (In111) Chloride Curium Netherlands, is a radiopharmaceutical presented as a solution for injection for intravenous use. It localizes in target tissues to enable scintigraphic imaging of infection, inflammation, tumors, or bone marrow activity in patients.

GNH USA supplies Indium (In111) Chloride Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Indium‑111 chloride is used in nuclear medicine to visualize pathological processes involving infection, inflammation, and malignancy. - Infection and inflammation: Enables precise localization of infectious foci and inflammatory lesions for diagnostic clarification. - Tumor imaging and staging: Provides high‑resolution gamma images to assess tumor presence, extent, and metastatic spread. - Bone marrow and leukocyte imaging: Labels autologous leukocytes to evaluate bone‑marrow activity and detect occult infections.

Adverse reactions are generally related to the radiopharmaceutical nature and the injection procedure.

Common Side Effects: - Mild injection site pain or erythema - Transient nausea or vomiting - Temporary headache or dizziness - Low‑grade fever - Mild fatigue - Brief flushing sensation

Serious or Rare Side Effects: - Radiation‑induced tissue injury at the injection site - Severe allergic reaction (anaphylaxis) - Significant hypotension or cardiovascular collapse - Hematologic toxicity in high cumulative doses - Organ‑specific radiation damage (e.g., renal) - Unexplained persistent fever or infection signs

Use of Indium‑111 chloride requires careful consideration of radiation safety and patient factors. - Radiation exposure: Minimize staff exposure and follow local radiation protection guidelines. - Pregnancy: Avoid use unless clearly justified, as fetal radiation risk is unknown. - Breastfeeding: Discontinue breastfeeding for an appropriate period after administration. - Renal impairment: Assess kidney function, as excretion may be altered. - Known hypersensitivity: Do not administer to patients with prior severe reactions to radiopharmaceuticals. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium‑111 chloride may interact with other agents that affect radiation dose or biodistribution.

Major Interactions (Avoid): - Concurrent administration of other gamma‑emitting radiopharmaceuticals that increase cumulative radiation exposure. - Strong chelating agents (e.g., EDTA) that may bind the radionuclide and alter distribution. - High‑dose steroids that could suppress leukocyte migration and reduce imaging accuracy.

Moderate Interactions (Monitor Closely): - Colony‑stimulating factors that may increase bone‑marrow uptake. - Iodinated contrast media used shortly before or after injection, potentially affecting image quality. - Anticoagulants that could increase risk of bleeding at the injection site.